Mendus

.Hero-module--bg-image--629a6.gbi--726045498-wQfB2mqMeKW2cmHfPrQqzZ:before { opacity: 1; background-image: url('/static/e62925564ecb1ec6ce1d956cde68e06b/44759/2026-granddad-child-reading-landscape-scaled.jpg'); }

Changing the course of cancer treatmentWe explore the power of the immune system to improve long-term survival of cancer patients, while preserving health and quality of life.
About us
Interview
<picture><source type="image/webp" srcSet="/static/3bf5d9a2043ea12a69d4fe6cc8971382/c690a/251121-BTG-3.webp 529w,/static/3bf5d9a2043ea12a69d4fe6cc8971382/7f271/251121-BTG-3.webp 1058w,/static/3bf5d9a2043ea12a69d4fe6cc8971382/1404b/251121-BTG-3.webp 2116w" sizes="(min-width: 2116px) 2116px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 2116px) 2116px, 100vw" decoding="async" loading="lazy" src="/static/3bf5d9a2043ea12a69d4fe6cc8971382/4ea1d/251121-BTG-3.jpg" srcSet="/static/3bf5d9a2043ea12a69d4fe6cc8971382/8abc6/251121-BTG-3.jpg 529w,/static/3bf5d9a2043ea12a69d4fe6cc8971382/25568/251121-BTG-3.jpg 1058w,/static/3bf5d9a2043ea12a69d4fe6cc8971382/4ea1d/251121-BTG-3.jpg 2116w" alt=""/></picture>
Interview with Professor Bjørn Tore GjertsenRead the full interview
<picture><source type="image/webp" srcSet="/static/87835c2a6d9e431dd70c08d9e7a6166f/f0323/Slide1.webp 204w,/static/87835c2a6d9e431dd70c08d9e7a6166f/d1b85/Slide1.webp 408w,/static/87835c2a6d9e431dd70c08d9e7a6166f/fa1e9/Slide1.webp 816w" sizes="(min-width: 816px) 816px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 816px) 816px, 100vw" decoding="async" loading="lazy" src="/static/87835c2a6d9e431dd70c08d9e7a6166f/dd920/Slide1.jpg" srcSet="/static/87835c2a6d9e431dd70c08d9e7a6166f/bf591/Slide1.jpg 204w,/static/87835c2a6d9e431dd70c08d9e7a6166f/f93a4/Slide1.jpg 408w,/static/87835c2a6d9e431dd70c08d9e7a6166f/dd920/Slide1.jpg 816w" alt=""/></picture>
Mendus presents data on vididencel in high-risk ovarian cancerRead More
<picture><source type="image/webp" srcSet="/static/42b195ffdd9d74710d6b6cee8959730e/f0323/Slide1.webp 204w,/static/42b195ffdd9d74710d6b6cee8959730e/d1b85/Slide1.webp 408w,/static/42b195ffdd9d74710d6b6cee8959730e/fa1e9/Slide1.webp 816w" sizes="(min-width: 816px) 816px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 816px) 816px, 100vw" decoding="async" loading="lazy" src="/static/42b195ffdd9d74710d6b6cee8959730e/dd920/Slide1.jpg" srcSet="/static/42b195ffdd9d74710d6b6cee8959730e/bf591/Slide1.jpg 204w,/static/42b195ffdd9d74710d6b6cee8959730e/f93a4/Slide1.jpg 408w,/static/42b195ffdd9d74710d6b6cee8959730e/dd920/Slide1.jpg 816w" alt=""/></picture>
Mendus publishes financial report for Q1 2026More details
<picture><source type="image/webp" srcSet="/static/d31662d107cdce24718eaaba15be5c6d/f0323/Slide1-3.webp 204w,/static/d31662d107cdce24718eaaba15be5c6d/d1b85/Slide1-3.webp 408w,/static/d31662d107cdce24718eaaba15be5c6d/fa1e9/Slide1-3.webp 816w" sizes="(min-width: 816px) 816px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 816px) 816px, 100vw" decoding="async" loading="lazy" src="/static/d31662d107cdce24718eaaba15be5c6d/dd920/Slide1-3.jpg" srcSet="/static/d31662d107cdce24718eaaba15be5c6d/bf591/Slide1-3.jpg 204w,/static/d31662d107cdce24718eaaba15be5c6d/f93a4/Slide1-3.jpg 408w,/static/d31662d107cdce24718eaaba15be5c6d/dd920/Slide1-3.jpg 816w" alt=""/></picture>
First Patient Enrolled in the VITAL-CML TrialRead More
<picture><source type="image/webp" srcSet="/static/5959bfccece3f5bf39cd44a02a0cafcf/f0323/Slide1-2.webp 204w,/static/5959bfccece3f5bf39cd44a02a0cafcf/d1b85/Slide1-2.webp 408w,/static/5959bfccece3f5bf39cd44a02a0cafcf/fa1e9/Slide1-2.webp 816w" sizes="(min-width: 816px) 816px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 816px) 816px, 100vw" decoding="async" loading="lazy" src="/static/5959bfccece3f5bf39cd44a02a0cafcf/dd920/Slide1-2.jpg" srcSet="/static/5959bfccece3f5bf39cd44a02a0cafcf/bf591/Slide1-2.jpg 204w,/static/5959bfccece3f5bf39cd44a02a0cafcf/f93a4/Slide1-2.jpg 408w,/static/5959bfccece3f5bf39cd44a02a0cafcf/dd920/Slide1-2.jpg 816w" alt=""/></picture>
Mendus Publishes Annual Report 2025Read the annual report
<picture><source type="image/webp" srcSet="/static/86a8de10ce8a727a1cc778385af30953/f0323/Slide1.webp 204w,/static/86a8de10ce8a727a1cc778385af30953/d1b85/Slide1.webp 408w,/static/86a8de10ce8a727a1cc778385af30953/fa1e9/Slide1.webp 816w" sizes="(min-width: 816px) 816px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 816px) 816px, 100vw" decoding="async" loading="lazy" src="/static/86a8de10ce8a727a1cc778385af30953/dd920/Slide1.jpg" srcSet="/static/86a8de10ce8a727a1cc778385af30953/bf591/Slide1.jpg 204w,/static/86a8de10ce8a727a1cc778385af30953/f93a4/Slide1.jpg 408w,/static/86a8de10ce8a727a1cc778385af30953/dd920/Slide1.jpg 816w" alt=""/></picture>
Living with CML: Solveig's StoryRead Solveig's Story
<picture><source type="image/webp" srcSet="/static/e37598a5254eef67fb058b3d9bb15cb8/eec5b/Whitebox-ONJCRI-Agreement.webp 306w,/static/e37598a5254eef67fb058b3d9bb15cb8/c01ac/Whitebox-ONJCRI-Agreement.webp 612w,/static/e37598a5254eef67fb058b3d9bb15cb8/57d26/Whitebox-ONJCRI-Agreement.webp 1224w" sizes="(min-width: 1224px) 1224px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 1224px) 1224px, 100vw" decoding="async" loading="lazy" src="/static/e37598a5254eef67fb058b3d9bb15cb8/5151d/Whitebox-ONJCRI-Agreement.jpg" srcSet="/static/e37598a5254eef67fb058b3d9bb15cb8/cfe57/Whitebox-ONJCRI-Agreement.jpg 306w,/static/e37598a5254eef67fb058b3d9bb15cb8/e53f8/Whitebox-ONJCRI-Agreement.jpg 612w,/static/e37598a5254eef67fb058b3d9bb15cb8/5151d/Whitebox-ONJCRI-Agreement.jpg 1224w" alt=""/></picture>
Mendus signs agreement with Olivia Newton-John Cancer Research InstituteMore details
<picture><source type="image/webp" srcSet="/static/2d6e7b9a1702b423b28cbfd9c9194c49/5e941/251201-GMP-ENG.webp 168w,/static/2d6e7b9a1702b423b28cbfd9c9194c49/4d24e/251201-GMP-ENG.webp 336w,/static/2d6e7b9a1702b423b28cbfd9c9194c49/1b4fb/251201-GMP-ENG.webp 671w" sizes="(min-width: 671px) 671px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 671px) 671px, 100vw" decoding="async" loading="lazy" src="/static/2d6e7b9a1702b423b28cbfd9c9194c49/ce447/251201-GMP-ENG.jpg" srcSet="/static/2d6e7b9a1702b423b28cbfd9c9194c49/e38b9/251201-GMP-ENG.jpg 168w,/static/2d6e7b9a1702b423b28cbfd9c9194c49/21c63/251201-GMP-ENG.jpg 336w,/static/2d6e7b9a1702b423b28cbfd9c9194c49/ce447/251201-GMP-ENG.jpg 671w" alt=""/></picture>
Press releaseMore details 
Interview
<picture><source type="image/webp" srcSet="/static/3bf5d9a2043ea12a69d4fe6cc8971382/c690a/251121-BTG-3.webp 529w,/static/3bf5d9a2043ea12a69d4fe6cc8971382/7f271/251121-BTG-3.webp 1058w,/static/3bf5d9a2043ea12a69d4fe6cc8971382/1404b/251121-BTG-3.webp 2116w" sizes="(min-width: 2116px) 2116px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 2116px) 2116px, 100vw" decoding="async" loading="lazy" src="/static/3bf5d9a2043ea12a69d4fe6cc8971382/4ea1d/251121-BTG-3.jpg" srcSet="/static/3bf5d9a2043ea12a69d4fe6cc8971382/8abc6/251121-BTG-3.jpg 529w,/static/3bf5d9a2043ea12a69d4fe6cc8971382/25568/251121-BTG-3.jpg 1058w,/static/3bf5d9a2043ea12a69d4fe6cc8971382/4ea1d/251121-BTG-3.jpg 2116w" alt=""/></picture>
Interview with Professor Bjørn Tore GjertsenRead the full interview
<picture><source type="image/webp" srcSet="/static/87835c2a6d9e431dd70c08d9e7a6166f/f0323/Slide1.webp 204w,/static/87835c2a6d9e431dd70c08d9e7a6166f/d1b85/Slide1.webp 408w,/static/87835c2a6d9e431dd70c08d9e7a6166f/fa1e9/Slide1.webp 816w" sizes="(min-width: 816px) 816px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 816px) 816px, 100vw" decoding="async" loading="lazy" src="/static/87835c2a6d9e431dd70c08d9e7a6166f/dd920/Slide1.jpg" srcSet="/static/87835c2a6d9e431dd70c08d9e7a6166f/bf591/Slide1.jpg 204w,/static/87835c2a6d9e431dd70c08d9e7a6166f/f93a4/Slide1.jpg 408w,/static/87835c2a6d9e431dd70c08d9e7a6166f/dd920/Slide1.jpg 816w" alt=""/></picture>
Mendus presents data on vididencel in high-risk ovarian cancerRead More

<picture><source type="image/webp" srcSet="/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/d7070/Startpage_1-NEW-1.webp 240w,/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/4ce17/Startpage_1-NEW-1.webp 480w,/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/95cd0/Startpage_1-NEW-1.webp 960w" sizes="(min-width: 960px) 960px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 960px) 960px, 100vw" decoding="async" loading="lazy" src="/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/49439/Startpage_1-NEW-1.jpg" srcSet="/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/ff13b/Startpage_1-NEW-1.jpg 240w,/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/28e6b/Startpage_1-NEW-1.jpg 480w,/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/49439/Startpage_1-NEW-1.jpg 960w" alt=""/></picture>
Gaining the 
upper handToday, tumor recurrence is the main cause of cancer-related deaths. We aim to reduce tumor recurrence by harnessing the immune system to act against residual cancer cells.
What we do

<picture><source type="image/webp" srcSet="/static/bfd9bafcd3660b03f3b72edb150264f7/ecbb3/Startpage_2.webp 450w,/static/bfd9bafcd3660b03f3b72edb150264f7/10d3d/Startpage_2.webp 900w,/static/bfd9bafcd3660b03f3b72edb150264f7/7d31d/Startpage_2.webp 1800w" sizes="(min-width: 1800px) 1800px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 1800px) 1800px, 100vw" decoding="async" loading="lazy" src="/static/bfd9bafcd3660b03f3b72edb150264f7/b37a5/Startpage_2.jpg" srcSet="/static/bfd9bafcd3660b03f3b72edb150264f7/ea40c/Startpage_2.jpg 450w,/static/bfd9bafcd3660b03f3b72edb150264f7/a3b1e/Startpage_2.jpg 900w,/static/bfd9bafcd3660b03f3b72edb150264f7/b37a5/Startpage_2.jpg 1800w" alt="&lt;p&gt;Two chemistry laboratory researchers, a young man and a young woman working together in a biology, chemistry research laboratory.= in a university. Focus on the laboratory equipment with the personnel in the background. Photographed in horizontal format.&lt;/p&gt;
"/></picture>
New ways to make a differenceWe apply our understanding of dendritic cell biology to design cancer immunotherapies that stimulate active immunity, the only long-lasting form of immunity.
About us

<picture><source type="image/webp" srcSet="/static/0237bef387e76cffaa6681d16a2b59c4/8cdf4/Startpage_3.webp 302w,/static/0237bef387e76cffaa6681d16a2b59c4/39272/Startpage_3.webp 603w,/static/0237bef387e76cffaa6681d16a2b59c4/0d01b/Startpage_3.webp 1206w" sizes="(min-width: 1206px) 1206px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 1206px) 1206px, 100vw" decoding="async" loading="lazy" src="/static/0237bef387e76cffaa6681d16a2b59c4/e579d/Startpage_3.jpg" srcSet="/static/0237bef387e76cffaa6681d16a2b59c4/8f82e/Startpage_3.jpg 302w,/static/0237bef387e76cffaa6681d16a2b59c4/d2caf/Startpage_3.jpg 603w,/static/0237bef387e76cffaa6681d16a2b59c4/e579d/Startpage_3.jpg 1206w" alt="&lt;p&gt;Molecular Structure. Science background. 3D Render&lt;/p&gt;
"/></picture>
Invest in future cancer careMendus is listed on NASDAQ Stockholm under the ticker symbol IMMU. You will find all relevant information on the Mendus share in our Investors section.
Investors

Latest newsNews and Events
No articles found

.FullWidthImage-module--bg-image-mobile--ba5fc.FullWidthImage-module--hide-in-mobile--9cd89.gbi--752554434-17tpfSfgWr9KKgMbXG9mYe:before { opacity: 1; background-image: url('/static/58920a993c01776af52e6d8a69a7452d/60e72/What-we-do_1-mobile-1.jpg'); }

What we do

Changing the course of cancer treatment

Interview with Professor Bjørn Tore Gjertsen

Mendus presents data on vididencel in high-risk ovarian cancer

Mendus publishes financial report for Q1 2026

First Patient Enrolled in the VITAL-CML Trial

Mendus Publishes Annual Report 2025

Living with CML: Solveig's Story

Mendus signs agreement with Olivia Newton-John Cancer Research Institute

Press release

Interview with Professor Bjørn Tore Gjertsen

Mendus presents data on vididencel in high-risk ovarian cancer

Gaining the upper hand

New ways to make a difference

Invest in future cancer care

Latest news

What we do

Gaining the
upper hand